Journal of Clinical Endocrinology & Metabolism, Vol 71, 994-1002, Copyright © 1990 by Endocrine Society

ARTICLES

Treatment with a somatostatin analog decreases pancreatic B-cell and whole body sensitivity to glucose

SE Kahn, LJ Klaff, MW Schwartz, JC Beard, RN Bergman, GJ Taborsky Jr and D Porte Jr
Department of Medicine, University of Washington, Seattle.

To determine the specific alteration in B-cell function caused by a somatostatin analog in man and to determine the effect of the induced insulin deficiency on insulin action, we administered octreotide (SMS 201-995; 50 micrograms twice daily) to nine healthy male subjects, aged 24-35 yr. B-Cell function was assessed by measuring the acute insulin response (AIR) to glucose (AIRglucose) at fasting glucose and to arginine (AIRarg) at glucose concentrations of fasting, approximately 14 and more than 28 mM after 2 (n = 7) and 8 days (n = 9) of octreotide. The AIRarg at more than 28 mM glucose (AIR500) is an estimate of B-cell secretory capacity, while the glucose level at which 50% of AIR500 occurs is termed PG50 and can provide an estimate of B- cell glucose sensitivity. Insulin sensitivity and the parameters describing glucose disposal were measured using Bergman's minimal model. Octreotide administration resulted in the development of mild fasting hyperglycemia, marked fasting hypoinsulinemia, as well as a marked reduction in AIRglucose [mean +/- SE; pretreatment, 260 +/- 48 pM; 1 day, 62 +/- 14 pM (P less than 0.005 vs. pretreatment); 8 days, 62 +/- 7 pM (P less than 0.005 vs. pretreatment)]. In addition, there was an associated marked reduction in iv glucose tolerance. While the AIRarg at fasting glucose (pretreatment, 233 +/- 27 pM; 2 days, 144 +/- 27 pM; 8 days 281 +/- 55 pM) and AIR500 (pretreatment 1000 +/- 178 pM; 2 days, 651 +/- 82 pM; 8 days, 1041 +/- 219 pM) remained unchanged, the AIRarg at 14 mM decreased significantly during octreotide [pretreatment 986 +/- 178 pM; 2 days, 363 +/- 62 pM (P less than 0.001 vs. pretreatment); 8 days, 623 +/- 130 pM (P less than 0.005 vs. pretreatment)], resulting in a rightward shift of the dose-response curve such that the estimated PG50 increased from 8.8 +/- 0.6 to 12.9 +/- 1.3 mM (P less than 0.05) after 2 days and was maintained for 8 days (11.2 +/- 0.8 mM; P less than 0.05 vs. pretreatment). Despite the development of marked insulin deficiency, the insulin sensitivity index (SI) did not change significantly (pretreatment, 11.34 +/- 1.59 x 10(- 5); 1 day, 10.01 +/- 2.28 x 10(-5); 7 days, 9.65 +/- 1.69 x 10(-5) min- 1/pM).(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				M. Cnop, J. Vidal, R. L. Hull, K. M. Utzschneider, D. B. Carr, T. Schraw, P. E. Scherer, E. J. Boyko, W. Y. Fujimoto, and S. E. Kahn Progressive Loss of {beta}-Cell Function Leads to Worsening Glucose Tolerance in First-Degree Relatives of Subjects With Type 2 Diabetes Diabetes Care, March 1, 2007; 30(3): 677 - 682. [Abstract] [Full Text] [PDF]

				K. M. Utzschneider, D. B. Carr, R. L. Hull, K. Kodama, J. B. Shofer, B. M. Retzlaff, R. H. Knopp, and S. E. Kahn Impact of Intra-Abdominal Fat and Age on Insulin Sensitivity and {beta}-Cell Function Diabetes, November 1, 2004; 53(11): 2867 - 2872. [Abstract] [Full Text] [PDF]

				N. G. Knowles, M. A. Landchild, W. Y. Fujimoto, and S. E. Kahn Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes Diabetes Care, February 1, 2002; 25(2): 292 - 297. [Abstract] [Full Text] [PDF]

				M. Afargan, E. T. Janson, G. Gelerman, R. Rosenfeld, O. Ziv, O. Karpov, A. Wolf, M. Bracha, D. Shohat, G. Liapakis, et al. Novel Long-Acting Somatostatin Analog with Endocrine Selectivity: Potent Suppression of Growth Hormone But Not of Insulin Endocrinology, January 1, 2001; 142(1): 477 - 486. [Abstract] [Full Text] [PDF]

				J. Radziuk Insulin Sensitivity and Its Measurement: Structural Commonalities among the Methods J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4426 - 4433. [Abstract] [Full Text]

				M. Sakamoto, Y. Higaki, Y. Nishida, A. Kiyonaga, M. Shindo, K. Tokuyama, and H. Tanaka Influence of mild exercise at the lactate threshold on glucose effectiveness J Appl Physiol, December 1, 1999; 87(6): 2305 - 2310. [Abstract] [Full Text] [PDF]

				A.N.M. Wymenga, B. Eriksson, P.I. Salmela, M.B. Jacobsen, E.J.D.G. Van Cutsem, R.H. Fiasse, M.J. Valimaki, J. Renstrup, E.G.E. de Vries, and K.E. Oberg Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms J. Clin. Oncol., April 1, 1999; 17(4): 1111 - 1111. [Abstract] [Full Text] [PDF]

				B. Ahrén and G. Pacini Age-Related Reduction in Glucose Elimination Is Accompanied by Reduced Glucose Effectiveness and Increased Hepatic Insulin Extraction in Man J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3350 - 3356. [Abstract] [Full Text]

				K. Filipsson, G. Pacini, A. J. W. Scheurink, and B. Ahren PACAP stimulates insulin secretion but inhibits insulin sensitivity in mice Am J Physiol Endocrinol Metab, May 1, 1998; 274(5): E834 - E842. [Abstract] [Full Text] [PDF]

				G. Pacini, G. Tonolo, M. Sambataro, M. Maioli, M. Ciccarese, E. Brocco, A. Avogaro, and R. Nosadini Insulin sensitivity and glucose effectiveness: minimal model analysis of regular and insulin-modified FSIGT Am J Physiol Endocrinol Metab, April 1, 1998; 274(4): E592 - E599. [Abstract] [Full Text] [PDF]

				R. L. Prigeon, S. E. Kahn, and D. Porte Jr. Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 819 - 823. [Abstract] [Full Text]

				K. Izumino, H. Sakamaki, M. Ishibashi, H. Takino, H. Yamasaki, Y. Yamaguchi, N. Chikuba, K. Matsumoto, S. Akazawa, K. Tokuyama, et al. Troglitazone Ameliorates Insulin Resistance in Patients with Werner's Syndrome J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2391 - 2395. [Abstract] [Full Text] [PDF]